Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | MMP13 | P45452 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1042327 | 0.91 | RAB9A (0.78) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5335238 | 0.89 | MEN1 (1.00) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5334358 | 0.87 | MEN1 (0.90) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5335606 | 0.86 | PKM (0.70) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5335876 | 0.86 | PKM (0.70) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5331977 | 0.85 | MMP13 (0.76) | MEN1KMT2ALMNAMMP13ALDH1A1 | |
| SCHEMBL1040934 | 0.85 | MMP13 (0.69) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL5335082 | 0.84 | MEN1 (0.90) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL4266241 | 0.82 | MMP13 (0.72) | MEN1KMT2ALMNAMAPK1MMP13 | |
| SCHEMBL3722808 | 0.82 | MEN1 (0.85) | MEN1KMT2ALMNAMAPK1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214712-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-6995151-B2 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE C | 2006-02-02 | — | — | US | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004006913-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362028-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002064547-A2 | ISOPHTHALIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025396-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP3 | MEN1 3554/4885KMT2A 3382/4885LMNA 3585/4885 |
| US-20020156061-A1 | Isophthalic acid derivatives as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | MEN1 4185/4885KMT2A 2496/4885LMNA 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.